Pheochromocytoma and paraganglioma: molecular testing and personalized medicine

Abstract : Purpose of review: Pheochromocytomas and paragangliomas (PPGL) are rare tumours, strongly associated with inherited susceptibility gene mutations, and presenting limited therapeutic options for patients with metastatic disease. This review discusses the recent developments in the characterization of PPGL genetic heterogeneity and associated tumourigenesis pathways, together with their potential clinical relevance. Recent findings: The mutational landscape of PPGL is now well defined, especially with the contribution of next generation sequencing (NGS). Up to 70% of these tumours harbour a germline or a somatic mutation in one of the numerous predisposing gene. In parallel, “omics” analyses have identified mutation-linked subsets of tumours substantially associated with molecular signatures suggesting new therapeutic targets for patients with a malignant transformation of the disease. Summary: In the near future, extended molecular testing of PPGL could be used to determine therapeutic approaches and assess diagnosis and prognosis biomarkers. Considering the current development of NGS-based genetic screening, this technology appears as a good option to improve both PPGL molecular diagnosis and patient management.
Liste complète des métadonnées

Littérature citée [48 références]  Voir  Masquer  Télécharger
Contributeur : Anne-Paule Gimenez-Roqueplo <>
Soumis le : vendredi 13 janvier 2017 - 11:12:24
Dernière modification le : lundi 18 décembre 2017 - 10:16:35
Document(s) archivé(s) le : vendredi 14 avril 2017 - 15:34:53


Burnichon et al.pdf
Fichiers produits par l'(les) auteur(s)




Anne-Paule Gimenez-Roqueplo, Alexandre Buffet, Nelly Burnichon. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Current Opinion in Oncology, Lippincott, Williams & Wilkins, 2016, 28 (1), pp.5-10. 〈10.1097/CCO.0000000000000249〉. 〈inserm-01434161〉



Consultations de la notice


Téléchargements de fichiers